C4B and cancer: To uncover the scope of influence caused by CH mutations, we overlapped them with actionable somatic mutations and found that 48 of 5933 (0.81%) CH mutations carried by 92 of 5100 (1.8%) cancer patients were also actionable somatic mutations.